Statistics

	Views
Phase II study of Regorafenib as single agent for the treatment of patients with metastatic colorectal cancer with any RAS or BRAF mutation and previously treated with FOLFOXIRI plus bevacizumab	10

Select a period of time:

	Views
Phase II study of Regorafenib as single agent for the treatment of patients with metastatic colorectal cancer with any RAS or BRAF mutation and previously treated with FOLFOXIRI plus bevacizumab	5

	Views
United States	5

	Views
Ashburn	2
Boardman	1

RUNA digital repository